Jan 23, 2024
Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)
Jan 17, 2024
Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium
Jan 15, 2024
Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox
Feb 10, 2021
Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7
Feb 07, 2021
Medivir Proposes Directed Issue of Approximately SEK 28 Million to the Company's Existing Specialist Investor LINC
Jan 11, 2021
Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant
Dec 11, 2020
Notice of extraordinary general meeting of Medivir AB (publ)
Dec 11, 2020
Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant
Nov 10, 2020
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2020
Oct 05, 2020
Medivir appoints Dr. Tom Morris as interim Chief Medical Officer
Jul 03, 2020
The European Commission has Granted Orphan Medicinal Product Designation in the EU for MIV-818
May 26, 2020
Medivir Appoints Yilmaz Mahshid as New CEO
May 06, 2020
FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
May 05, 2020
Resolutions at the Annual General Meeting in Medivir on 5 May 2020
Apr 30, 2020
Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
Apr 15, 2020
Medivir Announces Departure of Chief Medical Officer
Mar 16, 2020
Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset
Mar 10, 2020
First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study
Mar 02, 2020
Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818 in Patients With Advanced Liver Cancer
Feb 13, 2020
Medivir AB: Year End Report January-December 2019